In a report released yesterday, David Larsen from BTIG maintained a Buy rating on CryoPort (CYRX – Research Report), with a price target of $60.00. The company’s shares closed last Thursday at $24.17, close to its 52-week low of $21.61.
According to TipRanks.com, Larsen is ranked 0 out of 5 stars with an average return of -9.5% and a 32.3% success rate. Larsen covers the Technology sector, focusing on stocks such as Health Catalyst, American Well, and Sharecare.
Currently, the analyst consensus on CryoPort is a Strong Buy with an average price target of $57.00, representing a 125.3% upside. In a report issued on May 2, SVB Securities also maintained a Buy rating on the stock with a $45.00 price target.
See the top stocks recommended by analysts >>
CryoPort’s market cap is currently $1.22B and has a P/E ratio of -4.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Irvine, CA.
Read More on CYRX:
